|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
STRUCTURE-BASED DRUG DESIGN | ||||||||||||||||
December 06, 2000 | ||||||||||||||||
Cambridge Healthtech Institute, Cambridge, Massachusetts April 11-12, 2001 The wealth of information made available through efforts in structural genomics and advances in computation has allowed structure-based drug design to emerge as a valuable tool in medicinal chemistry. In the past combinatorial chemistry, coupled with high-throughput approaches, shifted attention away from the more structure-based methods. Large-scale determination of protein structures is reversing the drug discovery process by starting with the protein structure and using it to identify and design new ligands. It is the integration of structure-based methods, virtual screening, and combinatorial chemistry that will provide the basis for more efficient drug design in the future, significantly reducing the time of the design cycle and the cost per marketed drug. |
||||||||||||||||
Organized by: | Cambridge Healthtech Institute | |||||||||||||||
Invited Speakers: | Dr. David Bailey, De Novo Pharmaceuticals Ltd. Dr. Mark Murcko, Vertex Pharmaceuticals, Inc. Dr. Tomi K. Sawyer, ARIAD Pharmaceuticals, Inc. Dr. John H. van Drie, Pharmacia & Upjohn, Inc. Dr. Christian Lemmen, DuPont Pharmaceuticals Company Dr. Hans-Joachim Boehm, Hoffmann-La Roche Ltd. |
|||||||||||||||
Deadline for Abstracts: | March 9, 2001 | |||||||||||||||
Registration: | Available on-line | |||||||||||||||
E-mail: | jlaakso@healthtech.com | |||||||||||||||
Posted by: | Jennifer Laakso | |||||||||||||||
Host: | wks217.healthtech.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |